Raymor Industries Starts Production at Boisbriand, Quebec

Raymor Industries has completed on schedule the move of all of its current business activities and is now in production at its new 77,000 sq. ft. facility in Boisbriand, Quebec, a suburb of Montreal. The existing production units have all been calibrated and commissioned, and have already begun producing for clients at the new facility. Furthermore, the major expansion activities for Raymor’s metallic powders and coating divisions will be completed over the course of the current quarter. The move to the new facility was initiated in order to save costs and to facilitate the expansion of its single-walled carbon nanotubes (C-SWNT) and advanced materials production lines. The new facility costs 30% less to operate on a square foot basis as compared to the previous location, and is more strategically located to service Raymor’s existing and projected client base.

The existing production units which are now in production at the new facility include the following:

  • One high capacity unit for the production of high quality, reasonably priced C-SWNT for composite and other applications in the aerospace, defense, sports and recreation, and energy fields;
  • One plasma atomization unit for the production of highly spherical, very flowable and very pure titanium and titanium alloy powders for biomedical and aerospace applications;
  • One HVOF (High Velocity Oxy-Fuel) spray unit, used primarily for the coating of carbide-based materials in aerospace, power generation and other industrial applications;
  • One APS (Atmospheric Plasma Spraying) spray unit, for the coating of metals and ceramics onto critical components in various sectors, including aerospace and other specialized industries;
  • One VPS (Vacuum Plasma Spraying) spray unit for the coating of critical gas turbine components, severe service ball valves, and other equipment requiring very high quality metal and ceramic coatings.

With respect to the company’s previously-announced major expansion with new processing equipment, Raymor will complete the installation of the following operations over the course of this quarter:

  • A second plasma atomization unit for the production of spherical titanium powders, to meet the expanding demands of the orthopedic implant industry;
  • A second HVOF spray unit, specifically designed to meet the requirements of the aircraft landing gear industry;
  • A second APS spray unit, targeting aerospace, power generation and other industrial applications;
  • A second VPS spray unit, dedicated for the coating of orthopedic implants and other biomedical components;
  • A third APS/HVOF spray unit dedicated for the coating of print rollers and other long rotating shafts, bringing the total of all APS/HVOF spray units to five (5).

Commenting on the news, Stéphane Robert, President and CEO of Raymor Industries, had the following to say:

“With the completion of installations in our new facility and the purchase of new equipment which considerably increased our production capacity, coupled with new qualified personnel coming on board with the company, we are now in a much better position to capture significant market share in the aerospace, defense, biomedical and industrial sectors in all of our operating divisions. Clients have already begun to visit the new building, and have walked away very impressed with our facility and very enthusiastic about our capability to expand, particularly in our Nanotechnology division. With only certain key qualifications remaining, we have all the elements in place to sign long-term agreements with our customers.”

http://www.raymor.com

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.